%0 Journal Article
%T Multisite Validation of a Functional Assay to Adjudicate SCN5A Brugada Syndrome-Associated Variants.
%A Ma JG
%A O'Neill MJ
%A Richardson E
%A Thomson KL
%A Ingles J
%A Muhammad A
%A Solus JF
%A Davogustto G
%A Anderson KC
%A Shoemaker MB
%A Stergachis AB
%A Floyd BJ
%A Dunn K
%A Parikh VN
%A ChubbW H
%A Perrin MJ
%A Roden DM
%A Vandenberg JI
%A Ng CA
%A Glazer AM
%J Circ Genom Precis Med
%V 0
%N 0
%D 2024 Jul 2
%M 38953211
%F 7.465
%R 10.1161/CIRCGEN.124.004569
%X <B>UNASSIGNED: </B>Brugada syndrome is an inheritable arrhythmia condition that is associated with rare, loss-of-function variants in SCN5A. Interpreting the pathogenicity of SCN5A missense variants is challenging, and ≈79% of SCN5A missense variants in ClinVar are currently classified as variants of uncertain significance. Automated patch clamp technology enables high-throughput functional studies of ion channel variants and can provide evidence for variant reclassification.<BR><B>UNASSIGNED: </B>An in vitro SCN5A-Brugada syndrome automated patch clamp assay was generated and independently studied at Vanderbilt University Medical Center and Victor Chang Cardiac Research Institute. The assay was calibrated according to ClinGen Sequence Variant Interpretation recommendations using high-confidence variant controls (n=49). Normal and abnormal ranges of function were established based on the distribution of benign variant assay results. Odds of pathogenicity values were derived from the experimental results according to ClinGen Sequence Variant Interpretation recommendations. The calibrated assay was then used to study SCN5A variants of uncertain significance observed in 4 families with Brugada syndrome and other arrhythmia phenotypes associated with SCN5A loss-of-function.<BR><B>UNASSIGNED: </B>Variant channel parameters generated independently at the 2 research sites showed strong correlations, including peak INa density (R2=0.86). The assay accurately distinguished benign controls (24/25 concordant variants) from pathogenic controls (23/24 concordant variants). Odds of pathogenicity values yielded 0.042 for normal function and 24.0 for abnormal function, corresponding to strong evidence for both American College of Medical Genetics and Genomics/Association for Molecular Pathology benign and pathogenic functional criteria (BS3 and PS3, respectively). Application of the assay to 4 clinical SCN5A variants of uncertain significance revealed loss-of-function for 3/4 variants, enabling reclassification to likely pathogenic.<BR><B>UNASSIGNED: </B>This validated high-throughput assay provides clinical-grade functional evidence to aid the classification of current and future SCN5A-Brugada syndrome variants of uncertain significance.